Bladder & urothelial cancer
Oncology· 7 reviewed drugs· 7721 cited findings behind them
What the regulatory reviews cover
This library contains regulatory review documents for several drugs indicated for bladder and urothelial cancer. These include Padcev, Tecentriq, Bavencio, Adstiladrin, Balversa, Javlor, and Imfinzi. The reported outcomes vary by drug and trial design.
For instance, Padcev showed an Objective Response Rate (ORR) of 32.2. Bavencio demonstrated a Median overall survival (avelumab) of 21.4 compared to 14.3 for the comparator arm, representing a 31% Reduction in risk of death. Adstiladrin reported an Incidence of Complete Response (CR) at any time of 53.4. Balversa had an Objective Response Rate (CR + PR) of 45.6 compared to 11.5 for Chemotherapy. Javlor showed a Median OS (VFL+CAPE arm) of 13.9 versus 11.7 for the CAPE arm. It is important to note that these figures are derived from different studies and are not directly comparable head-to-head.
The drugs — one cited result each
| Padcev Astellas Pharma Inc. | Objective Response Rate (ORR): 32.2 Astellas Pharma Inc. — Padcev FDA Review (BLA761137, ORIG 1,, p.24 |
| Tecentriq Roche Holding AG | Confirmed ORR (all patients): 14.8% GENENTECH INC — Tecentriq FDA Summary Review (NDA/BLA 761034, p.4 |
| Bavencio Merck B V | Median overall survival (avelumab): 21.4 EMD SERONO INC — Bavencio FDA Review (NDA/BLA 761049, 2020), p.107 |
| Adstiladrin Ferring A S | Incidence of Complete Response (CR) at any time: 53.4 Ferring A S — Adstiladrin EMA EPAR public assessment report, p.73 |
| Balversa Johnson & Johnson | Objective Response Rate (CR + PR): 45.6 EMA EPAR, p.115 |
| Javlor Pierre Fabre Medicament | Median OS (VFL+CAPE arm): 13.9 Pierre Fabre Medicament — Javlor EMA EPAR variation assessme, p.29 |
| Imfinzi AstraZeneca PLC | ORR in overall study population (excluding 10 patients): 16.9 AstraZeneca PLC — Imfinzi FDA Review (BLA761069, ORIG 1, 201, p.42 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.